Genentech, Inc.
NEWS
Tecentriq’s Phase III results gives Genentech a lead for potentially becoming the first-line treatment for squamous non-small cell lung cancer.
John Reed, who for five years has led Roche’s Pharma Research and Early Development (pRED) research group, is stepping down for personal reasons.
Viela Bio was spun out of AstraZeneca’s MedImmune with a Series A financing of up to $250 million.
The study assessed two doses of RG7716 versus ranibizumab standard of care given as monthly intravitreal injections.
Genentech said the Phase III combination therapy improved progression-free survival by 26 percent in mRCC patients whose disease expressed a PD-L1 protein.
2017 was the second-best year for FDA approvals since 1996.
The fact that Roche has separate R&D units has been the topic of second-guessing on the part of observers and analysts.
A little less than two years after tying up a multi-billion deal with Sanofi, DiCE Molecules scored another collaborative deal.
A look at the latest batch of FDA approvals this year.
JOBS
IN THE PRESS